الفهرس Only 14 pages are availabe for public view
 |  | from | 193 |  |  |
| | | from | 193 | | |
Abstract
Ovarian carcinoma is the leading cause of morbidity and mortality from gynecologic malignancy in the U.S. In 2004 the American Cancer Society estimated that approximately 25580 women will be newly diagnosed with ovarian carcinoma, and approximately 16090 women will die from this disease. (Everett, 2005).
Primary cytoreductive surgery followed by platinum chemotherapy represent the standard treatment for patients with advanced epithelial ovarian carcinoma. However, even if up to 80 % of women with advanced disease respond to the therapeutic strategy, most such patients will relapse or die of complication associated with disease progression (Loizzi et al., 2005).